In April 2022, researchers from Queens Hospital Center (Internal Medicine), Icahn School of Medicine at Mount Sinai (Internal Medicine), Kettering Medical Center (Internal Medicine), Rawal Institute of Health Services (Medicine), Weill Cornell Medicine (Cardiology/Medicine), and Queens Hospital Center (Cardiology) examined the outcomes of end-stage renal disease (ESRD) patients requiring a left ventricular assist device (LVAD)…
Login in to view this article:
You need to be logged in to view the rest of this article. Don't have an account? Register for one below.
Subscribe
0 Comments
Oldest
Sponsored Links
